Repare Therapeutics Announces Board Changes and FD Disclosure
TipRanks16:36 ET
Express News | Repare Therapeutics Appoints Steven H. Stein, M.d. to Its Board of Directors
Reuters16:05 ET
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation
TipRanksApr 21 09:35 ET
Repare Therapeutics Inc.'s (NASDAQ:RPTX) Market Cap Dropped US$21m Last Week; Private Equity Firms Bore the Brunt
Yahoo FinanceApr 20 09:43 ET
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination with gemcitabine plus oxaliplatin (GemOx) versus MabThera/Rituxan (rituxi
BenzingaApr 15 08:56 ET
Form 144 | Repare Therapeutics(RPTX.US) Officer Proposes to Sell 481.42K in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 26, $Repare Therapeutics(RPTX.US)$ Officer Segal Lloyd Mitchell intends to sell 99,466 shares of its common stock on Mar 26, with a total market value of approximately $481
moomoo NewsMar 26 14:55 ET
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
Stockhouse Mar 17 11:00 ET
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)--$RPTX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. ("Repare"
BusinesswireMar 15 14:35 ET
Little Excitement Around Repare Therapeutics Inc.'s (NASDAQ:RPTX) Revenues As Shares Take 30% Pounding
Repare Therapeutics Inc. (NASDAQ:RPTX) shares have had a horrible month, losing 30% after a relatively good period beforehand. The drop over the last 30 days has capped off a tough year for shareho
Simply Wall StMar 12 06:13 ET
Buy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts Ahead
TipRanksMar 8 06:35 ET
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming
BusinesswireFeb 29 07:05 ET
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)
TipRanksFeb 28 14:50 ET
Repare Therapeutics Reports Promising 2023 Progress
TipRanksFeb 28 11:37 ET
Recap: Repare Therapeutics Q4 Earnings
Repare Therapeutics (NASDAQ:RPTX) reported its Q4 earnings results on Wednesday, February 28, 2024 at 07:05 AM.Here's what investors need to know about the announcement.EarningsRepare Therapeutics mis
BenzingaFeb 28 09:40 ET
Repare Therapeutics GAAP EPS of -$0.67 Misses by $0.34, Revenue of $13.05M Misses by $5.88M
Seeking AlphaFeb 28 07:50 ET
Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023
Yahoo FinanceFeb 28 07:36 ET
Repare Therapeutics: Runway to Fund Operations Into Mid-2026 >RPTX
Repare Therapeutics: Runway to Fund Operations Into Mid-2026 >RPTX
Dow JonesFeb 28 07:07 ET
Repare Therapeutics 4Q Loss/Shr 67c >RPTX
Repare Therapeutics 4Q Loss/Shr 67c >RPTX
Dow JonesFeb 28 07:05 ET
Press Release: Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--February 28, 2024-- Repare Therapeutics Inc
Dow JonesFeb 28 07:05 ET
Express News | HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
Moomoo 24/7Feb 21 06:44 ET
No Data
No Data